Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 10Meningioma 4Gastro-enteropancreatic neuroendocrine tumor 3Prostatic Neoplasms 2Pheochromocytoma 2Paraganglioma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Medulloblastoma 2Glioma 2Ependymoma 2Adenoma, Islet Cell 2Stomach Neoplasms 1Sarcoma, Synovial 1Recurrence 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1Polymorphism, Genetic 1Osilodrostat 1Nutrition Assessment 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hypertension × lutetium Lu 177 dotatate × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡